2022
DOI: 10.3390/jof8080846
|View full text |Cite
|
Sign up to set email alerts
|

Cryptococcus neoformans Prp8 Intein: An In Vivo Target-Based Drug Screening System in Saccharomyces cerevisiae to Identify Protein Splicing Inhibitors and Explore Its Dynamics

Abstract: Inteins are genetic mobile elements that are inserted within protein-coding genes, which are usually housekeeping genes. They are transcribed and translated along with the host gene, then catalyze their own splicing out of the host protein, which assumes its functional conformation thereafter. As Prp8 inteins are found in several important fungal pathogens and are absent in mammals, they are considered potential therapeutic targets since inhibiting their splicing would selectively block the maturation of funga… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 61 publications
0
1
0
Order By: Relevance
“…One major question to be addressed is whether the lack of apparent cytotoxicity will translate into similarly low toxicity in other cell types and animal models. Pharmacological modulation of splicing is an exciting area for treatment of genetic disorders[16], cancer[23], and infectious disease[73]. Despite ongoing clinical trials investigating inhibition of splicing in cancers, and the approval of the gain of function splicing modulator risdiplam for treating spinal muscular atrophy[43], our ability to selectively target splicing with small moleclues is in its infancy.…”
Section: Discussionmentioning
confidence: 99%
“…One major question to be addressed is whether the lack of apparent cytotoxicity will translate into similarly low toxicity in other cell types and animal models. Pharmacological modulation of splicing is an exciting area for treatment of genetic disorders[16], cancer[23], and infectious disease[73]. Despite ongoing clinical trials investigating inhibition of splicing in cancers, and the approval of the gain of function splicing modulator risdiplam for treating spinal muscular atrophy[43], our ability to selectively target splicing with small moleclues is in its infancy.…”
Section: Discussionmentioning
confidence: 99%